The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.

The Virtual Biotech, a multi-agent AI system, improves drug development success rates by 48% and reduces adverse events by 32% through integrated analysis of biological data.

• Why it matters: Fragmented tools hinder efficient evidence synthesis across biological scales in drug discovery, delaying the development of effective therapies.
• What they did: The Virtual Biotech employs AI agents modeled on a drug company structure to analyze over 55,000 trials, propose therapeutic strategies, and interpret trial failures across various disease contexts.
• The result: This approach enables transparent, multiscale decision-making that enhances therapeutic development, offering insights into target selection, safety, and mechanisms of failure.